A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer L Sun et al, JAMA Oncology, October 3, 2019

Main|Search|PHGKB




Last Posted: Oct 04, 2019

---

• A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
  L Sun et al, JAMA Oncology, October 3, 2019
• After a Breast Cancer Diagnosis, Men May Be More Likely to Die than Women
  NCI, October 2, 2019
• Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
  Gail Mitchell H et al. Journal of the National Cancer Institute 2018 110(9) 994-1002
• New name for breast-cancer syndrome could help to save lives.
  Pritchard Colin C et al. Nature 2019 571(7763) 27-29
• ---Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy.
  Sjöström Martin et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep
• A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.
  Kunst Natalia R et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Oct 22(10) 1102-1110
• Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
  Farkas Amy et al. Journal of women's health (2002) 2019 Sep
• Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
  Wei Xiaoxia et al. Clinical drug investigation 2019 Sep
• Hereditary breast cancer: screening and risk reducing surgery.
  Renzulli Matteo et al. Gland surgery 2019 Sep 8(Suppl 3) S142-S149
• Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
  Brédart Anne et al. BMJ open 2019 Sep 9(9) e029926

more